Health & Medicine

STAT+: How an outsider crept into Eli Lilly's top ranks - and plans to drive its business forward

28 sec read161 views0 listens

Eli Lilly unexpectedly acquired Loxo Oncology for $8 billion in 2019, bringing not just cancer drugs and research but also key executives like Jacob Van Naarden into its leadership, marking an uncommon "acqui-hire" strategy in the pharmaceutical industry. This move underscores the value of strategic talent acquisition in driving business forward, highlighting a significant shift for content creators to note when covering corporate strategies in pharma.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

AI & Machine LearningMay 124 sec read

Musk vs. Altman Trial Opens in Oakland as Jury Hears Competing Accounts of OpenAI's Founding Mission

Elon Musk's trial against OpenAI and its leadership began in Oakland, with Musk arguing that the organization misused his charitable donations when transitioning to a for-profit model. This case is crucial as it could redefine corporate governance an...

Ali Nemati

Cybersecurity11 hours ago28 sec read

AI risk is not just a technology problem: New research shows why leadership matters more than controls

New research from IANS and Artico Search reveals that effective management of AI risks in enterprises depends more on organizational readiness, including leadership understanding and governance structures, rather than just technical security controls...

Ali Nemati

Legal & Policy1 day ago26 sec read

What the public thinks of the Supreme Court

The Marquette Law School Poll reveals a 47% approval rating for the Supreme Court, with significant partisan divides: 74% of Republicans approve compared to only 22% of Democrats. Public perception of the court's alignment with President Trump also v...

Ali Nemati